Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double Blind, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections With a Focus on Patients With Infections Due to Methicillin-resistant Staphylococcus Aureus.

Next Previous
X
Search
Trial Profile

A Phase 3, Randomized, Double Blind, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Complicated Gram Positive Skin and Skin Structure Infections With a Focus on Patients With Infections Due to Methicillin-resistant Staphylococcus Aureus.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 31 Mar 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telavancin (Primary) ; Vancomycin
  • Indications Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections; Surgical wound infections
  • Focus Registrational; Therapeutic Use
  • Acronyms ATLAS-I
  • Sponsors Theravance Biopharma

    • Most Recent Events

    • 01 Sep 2017 Results of post hoc analysis of data from the ATLAS and ATTAIN trials assessing efficacy and safety of Telavancin in patients with Concurrent Staphylococcus aureus Bacteremia, were published in the Infectious Diseases and Therapy.
    • 09 May 2016 According to a Theravance Biopharma media release, the US FDA has approved the company's sNDA for VIBATIV (telavancin) to expand the product's label to include data describing the treatment of patients with concurrent Staphylococcus aureus bacteremia in both of the antibiotic's currently approved indications in the United States (HABP/VABP). The sNDA was approved based on combined data from the ATLAS I and II and ATTAIN I and II trials.
    • 10 Sep 2015 According to Theravance Biopharma media release, the US FDA has accepted for filing the company's supplemental NDA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top